Close

AbbVie (ABBV) Announces FDA Approval for Addition of Moderate to Severe Fingernail Psoriasis Data to HUMIRA Prescribing Information

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. TSLA
2. SPY
3. GM
4. SPOT
5. AMZN
6. SHW
7. AAPL
8. IBM
9. MINN
10. NVDA


Go back to AbbVie (ABBV) Announces FDA Approval for Addition of Moderate to Severe Fingernail Psoriasis Data to HUMIRA Prescribing Information
AbbVie (NYSE: ABBV) Delayed: 169.54 +1.65 (0.98%)
Previous Close $167.89    52 Week High $68.12 
Open $168.59    52 Week Low $50.71 
Day High $170.37    P/E 36.78 
Day Low $168.22    EPS $4.61 
Volume 4,084,107